Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Anti-CGRP antibodies: a new approach to migraine prevention

(2014) Uwe Reuter   LANCET NEUROLOGY

Possible site of action of CGRP antagonists in migraine

(2011) Peer Tfelt-Hansen et al.   CEPHALALGIA

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

(2011) David J Hewitt et al.   CEPHALALGIA

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

(2011) Ann C. Raddant et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

(2010) C. A. Salvatore et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Current practice and future directions in the prevention and acute management of migraine

(2010) Peter J Goadsby et al.   LANCET NEUROLOGY

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology

Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects

(2010) Kayi Y. Chan et al.   PHARMACOLOGY & THERAPEUTICS

Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)

(2009) Simon R. Sinclair et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Calcitonin Gene-Related Peptide8-37 Antagonizes Capsaicin-Induced Vasodilation in the Skin: Evaluation of a Human in Vivo Pharmacodynamic Model

(2008) B. J. Van der Schueren et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET